Patents Examined by Zachary Skelding
  • Modified T cell receptors and related materials and methods
    Patent number: 9128080
    Abstract: The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: September 8, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paul F. Robbins, Richard A. Morgan, Steven A. Rosenberg
  • Purified antibody composition
    Patent number: 9102723
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: August 11, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Min M Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Multispecific deimmunized CD3-binders
    Patent number: 9102736
    Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: August 11, 2015
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Robert Hofmeister, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Christian Itin, Patrick Bäuerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
  • Purified antibody composition
    Patent number: 9096666
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: August 4, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Min M Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Antibodies to MASP-2
    Patent number: 9096676
    Abstract: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognizing said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to methods of producing said antibodies, methods of inhibiting MASP-2 activity as well as to pharmaceutical compositions comprising the MASP-2 antibodies.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: August 4, 2015
    Assignee: Helion Biotech APS
    Inventors: Flemming Larsen, Ulla Wahlers
  • Identifcation of CD8 T cells that are CD161and/or IL18R?and have rapid drug efflux capacity
    Patent number: 9090875
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: July 28, 2015
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
    Patent number: 9078843
    Abstract: The present invention is directed to an isolated T-Cell Receptor constant domain and to peptides derived therefrom and recombinant constructs encoding same, effective in therapy of T cell mediated inflammatory disease, autoimmunity and graft rejection. Therapeutic and prophylactic vaccine compositions and methods utilizing these proteins and peptides, DNA vaccines encoding same and T cell vaccines thereof are further provided.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: July 14, 2015
    Inventors: Irun R. Cohen, Francisco J. Quintana
  • Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
    Patent number: 9072716
    Abstract: The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: July 7, 2015
    Assignee: The United States of America, as represented by the Secretary Department of Health by Human Servies
    Inventors: Warren Strober, Ivan Fuss, Peter Mannon, Jan Preiss, Raj Puri, Koji Kawakami, Stefan Fichtner-Feigl, Atsushi Kitani
  • Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy
    Patent number: 9075044
    Abstract: Compositions and methods are provided for inhibiting T cell mediated destruction of virally transduced, trangene containing cells.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: July 7, 2015
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Katherine A. High, Marcela V. Maus, Federico Mingozzi, Daniel J. Hui
  • Methods of administering anti-TNF? antibodies
    Patent number: 9073987
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: July 7, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Antibody neutralizers of human granulocyte macrophage colony stimulating factor
    Patent number: 9067993
    Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: June 30, 2015
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Julia Hepp, Eva Vieser, Silke Petsch, Steven Zeman, Andreas Wolf, Sandra Bruckmaier
  • Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
    Patent number: 9061005
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: June 23, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Antigen-specific long-term memory T-cells
    Patent number: 9057054
    Abstract: The present invention provides compositions, methods, and systems for generating antigen-specific long-term memory T-cells using mTOR pathway inhibitors. The present invention provides compositions, systems, and methods for administering antigen-specific long-term memory T-cells to a subject (e.g., to a subject with cancer in adoptive transfer type of procedures).
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: June 16, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Yi Zhang
  • Antibodies to TNF-? and use thereof
    Patent number: 9056905
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-?. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-TNF-? antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-TNF-? antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-TNF-? antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with TNF-?.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: June 16, 2015
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Katie Olson, Ben Dutzar, Anne Elisabeth Carvalho Jensen, Leon Garcia-Martinez, Ethan Ojala, John Latham
  • Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
    Patent number: 9052312
    Abstract: The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumor necrosis factor alpha (TNF? or TNF) treatment to assess the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNF? treatment.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: June 9, 2015
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Zoltán Konthur, Hans Lehrach, Karl Skriner
  • Antagonists against TNFR1 and methods of use therefor
    Patent number: 9028822
    Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: May 12, 2015
    Assignee: Domantis Limited
    Inventors: Neil D. Brewis, Benjamin P. Woolven, Steve Holmes, Ian M. Tomlinson, Jennifer Lee, Carolyn Enever, Amrik Basran, Kate Jones, Ruud de Wildt, Stanislas Blein
  • T cell receptor-deficient T cell compositions
    Patent number: 9028812
    Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Dartmouth College
    Inventor: Charles L. Sentman
  • Methods of administering anti-TNF? antibodies
    Patent number: 9017680
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: April 28, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
    Patent number: 9017679
    Abstract: Compositions and methods utilizing immunomodulating agents can either stimulate or indirectly augment the immune system or have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used to treat disease caused by asthma and chronic inflammation such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: April 28, 2015
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Vadim Deyev, Robert Levy
  • Method of expanding double negative T cells
    Patent number: 9018004
    Abstract: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8+ and CD4+ T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T cell mitogen in a culture medium comprising an agent that can stimulate DN T cell growth; (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the T cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble T cell mitogen. The DN T cells obtained by the method are useful in a variety of applications including the treatment of cancer, infectious diseases, graft versus host disease and autoimmune disease.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: April 28, 2015
    Assignee: University Health Network
    Inventors: Li Zhang, Mei Han, Pouneh Dokouhaki